{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:15:05Z","timestamp":1784142905111,"version":"3.55.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The positive feedback loop between cancer stemness and the hypoxic microenvironment is a critical driver of hepatocellular carcinoma (HCC) progression. Analyzing their interaction in HCC is crucial to characterize immune microenvironment features, uncover molecular heterogeneity patterns, and develop targeted interventions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The TCGA-LIHC cohort (n=340) were stratified through consensus clustering of stemness- and hypoxia-related genes (SHRGs) identified by one-class logistic regression and weighted gene co-expression network analyses. Subsequently, a stemness- and hypoxia-related prognostic index (SHRPI) was constructed using random forest, and Cox regression analyses, with its prognostic significance assessed in two other independent cohorts: our NC-LT cohort comprising 180 liver transplant (LT) patients with HCC beyond Milan criteria, and the GSE104580 cohort containing 147 HCC patients treated with transcatheter arterial chemoembolization (TACE). A prognostic nomogram incorporating SHRPI was developed, and externally validated in the GSE14520 cohort (n=242). Systematic profiling of immune microenvironment features and immunotherapy responsiveness in SHRPI subgroups was performed, followed by pharmacogenomic screening and molecular docking to identify optimal therapies. After single-cell transcriptomic analysis, functional validation assays were conducted to confirm the role of G6PD, a key SHRPI component.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>SHRGs-based clustering revealed two clusters exhibiting distinct prognoses, functional annotations, genomic alterations, and immune microenvironment features. SHRPI served as an independent risk factor for both overall survival in HCC patients and recurrence-free survival in LT patients beyond Milan criteria. It demonstrated strong predictive power for TACE responsiveness. The SHRPI-integrated nomogram achieved robust performance in external validation. High SHRPI level was associated with a more immunosuppressive tumor microenvironment and poorer immunotherapy responsiveness. Pharmacogenomic and molecular docking analyses identified BI2536 as the most promising therapeutic agent for this high-SHRPI subgroup. Further experiments established that G6PD serves as a key therapeutic target for hypoxia-driven stemness maintenance in HCC by functioning as a stemness regulator that interacts with HIF-1\u03b1 to form a positive feedback loop under hypoxia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provides further insights into stemness-hypoxia interaction in HCC and delivers a clinically applicable predictive tool for prognosis. BI2536\u2019s synergy potential and the therapeutic value of G6PD targeting in stemness regulation advance individualized therapeutic strategies for HCC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1669275","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:31:17Z","timestamp":1758259877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Stemness- and hypoxia-based prognostic stratification index reveals G6PD as a regulator of hypoxia-driven stemness in hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Mingwei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunbin","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.10.018","article-title":"Unraveling the tumor-initiating cells in hepatocellular carcinoma","volume":"42","author":"Tsui","year":"2024","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour evolution in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","article-title":"Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications","volume":"19","author":"Lee","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0293-2","article-title":"Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update","volume":"17","author":"Clara","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","article-title":"N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells\u2019 Properties and lenvatinib resistance through WNT\/beta-catenin and hippo signaling pathways","volume":"164","author":"Wang","year":"2023","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/hep.32629","article-title":"Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications","volume":"78","author":"Lam","year":"2023","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.710","article-title":"Intricate relationship between cancer stemness, metastasis, and drug resistance","author":"Dakal","year":"2020","journal-title":"MedComm"},{"key":"B10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-023-00848-6","article-title":"Targeting hypoxia-inducible factors: therapeutic opportunities and challenges","volume":"23","author":"Yuan","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00587-8","article-title":"The effect of HIF on metabolism and immunity","volume":"18","author":"Taylor","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3320","article-title":"HIF induces human embryonic stem cell markers in cancer cells","volume":"71","author":"Mathieu","year":"2011","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","article-title":"Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150846","article-title":"Targeting HIF-1alpha abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues","volume":"132","author":"Bailey","year":"2022","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3726","article-title":"Hypoxia and the extracellular matrix: drivers of tumour metastasis","volume":"14","author":"Gilkes","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611058","article-title":"Hypoxic characteristic in the immunosuppressive microenvironment of hepatocellular carcinoma","volume":"12","author":"Mo","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.66913","article-title":"Integrated machine learning and bioinformatic analyses constructed a novel stemness-related classifier to predict prognosis and immunotherapy responses for hepatocellular carcinoma patients","volume":"18","author":"Chen","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1186\/s12885-022-10195-1","article-title":"A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107694","article-title":"Multi-cohort validation study of a four-gene signature for risk stratification and treatment response prediction in hepatocellular carcinoma","volume":"167","author":"Liu","year":"2023","journal-title":"Comput Biol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1236435","article-title":"Single-cell RNA sequencing identifies a novel proliferation cell type affecting clinical outcome of pancreatic ductal adenocarcinoma","volume":"13","author":"Ye","year":"2023","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7150\/jca.100922","article-title":"Technical and biological biases in bulk transcriptomic data mining for cancer research","volume":"16","author":"Liu","year":"2025","journal-title":"J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1038\/s41467-025-59745-8","article-title":"Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria","volume":"16","author":"Ling","year":"2025","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine learning identifies stemness features associated with oncogenic dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13059-022-02648-4","article-title":"Exaggerated false positives by popular differential expression methods when analyzing human population samples","volume":"23","author":"Li","year":"2022","journal-title":"Genome Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"B29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","article-title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","volume":"9","author":"Schubert","year":"2018","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"bbaa176","DOI":"10.1093\/bib\/bbaa176","article-title":"Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response","volume":"22","author":"Hu","year":"2021","journal-title":"Brief Bioinform"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.922195","article-title":"A novel immune-related gene signature to identify the tumor microenvironment and prognose disease among patients with oral squamous cell carcinoma patients using ssGSEA: A bioinformatics and biological validation study","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.37","article-title":"Decision curve analysis","volume":"313","author":"Fitzgerald","year":"2015","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2117-z","article-title":"An open-source drug discovery platform enables ultra-large virtual screens","volume":"580","author":"Gorgulla","year":"2020","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2183-2","article-title":"The gluconeogenic enzyme PCK1 phosphorylates INSIG1\/2 for lipogenesis","volume":"580","author":"Xu","year":"2020","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41467-019-14052-x","article-title":"Divergent mutational processes distinguish hypoxic and normoxic tumours","volume":"11","author":"Bhandari","year":"2020","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.939542","article-title":"Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.3390\/cancers15092586","article-title":"In vitro and in silico analysis of epithelial-mesenchymal transition and cancer stemness as prognostic markers of clear cell renal cell carcinoma","volume":"15","author":"Sharma","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2079","article-title":"Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma","volume":"6","author":"Kim","year":"2022","journal-title":"Hepatol Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.7150\/thno.54648","article-title":"Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma","volume":"11","author":"Dai","year":"2021","journal-title":"Theranostics"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101332","article-title":"PLK1 inhibition-based combination therapies for cancer management","volume":"16","author":"Su","year":"2022","journal-title":"Transl Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1602752","article-title":"PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10238-024-01538-2","article-title":"CRISPR screening and cell line IC50 data reveal novel key genes for trametinib resistance","volume":"25","author":"Liu","year":"2024","journal-title":"Clin Exp Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"10313","DOI":"10.3390\/ijms221910313","article-title":"RHAMM is a multifunctional protein that regulates cancer progression","volume":"22","author":"Messam","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2103","article-title":"HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells","volume":"74","author":"Tilghman","year":"2014","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201802186R","article-title":"Hyaluronan-mediated motility receptor confers resistance to chemotherapy via TGFbeta\/Smad2-induced epithelial-mesenchymal transition in gastric cancer","volume":"33","author":"Zhang","year":"2019","journal-title":"FASEB J"},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.4196\/kjpp.24.275","article-title":"Hyaluronan-mediated motility receptor-mediated aerobic glycolysis enhances stem-like properties and chemoresistance in lung adenocarcinoma","volume-title":"Korean J Physiol Pharmacol","author":"Yu","year":"2025"},{"key":"B51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl6083","article-title":"HMMR triggers immune evasion of hepatocellular carcinoma by inactivation of phagocyte killing","volume-title":"Sci Adv","author":"Wu","year":"2024"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24465","article-title":"Diverse roles of UBE2S in cancer and therapy resistance: Biological functions and mechanisms","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0236","article-title":"UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL","volume":"30","author":"Zhang","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6431","article-title":"UBE2S promotes Malignant properties via VHL\/HIF-1alpha and VHL\/JAK2\/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma","volume":"12","author":"Wu","year":"2023","journal-title":"Cancer Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/cancers14235722","article-title":"Biological functions of the DNA glycosylase NEIL3 and its role in disease progression including cancer","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096265896231226062212","article-title":"Transcription factor MAZ potentiates the upregulated NEIL3-mediated aerobic glycolysis, thereby promoting angiogenesis in hepatocellular carcinoma","volume":"24","author":"Zhang","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"B58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00251-022-01277-2","article-title":"SNHG3 regulates NEIL3 via transcription factor E2F1 to mediate Malignant proliferation of hepatocellular carcinoma","volume":"75","author":"Zhang","year":"2023","journal-title":"Immunogenetics"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.5b00202","article-title":"A Role for the Fifth G-Track in G-Quadruplex Forming Oncogene Promoter Sequences during Oxidative Stress: Do These \u201cSpare Tires\u201d Have an Evolved Function","volume":"1","author":"Fleming","year":"2015","journal-title":"ACS Cent Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-023-00863-2","article-title":"The pentose phosphate pathway in health and disease","volume":"5","author":"TeSlaa","year":"2023","journal-title":"Nat Metab"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01184-8","article-title":"The hepatic clock synergizes with HIF-1alpha to regulate nucleotide availability during liver damage repair","volume":"7","author":"Peng","year":"2025","journal-title":"Nat Metab"},{"key":"B62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40170-023-00311-5","article-title":"A feedback loop of PPP and PI3K\/AKT signal pathway drives regorafenib-resistance in HCC","volume":"11","author":"Yang","year":"2023","journal-title":"Cancer Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01406-2","article-title":"METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma","volume":"32","author":"Jin","year":"2025","journal-title":"Cell Death Differ"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11212","article-title":"Up-regulation of the pentose phosphate pathway and HIF-1alpha expression during neural progenitor cell induction following glutamate treatment in rat ex vivo retina","volume":"44","author":"Tokuda","year":"2020","journal-title":"Cell Biol Int"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14241","article-title":"Nrf2 promotes breast cancer cell migration via up-regulation of G6PD\/HIF-1alpha\/Notch1 axis","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15537","article-title":"Novel evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer","volume":"24","author":"Feng","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e3580","DOI":"10.1002\/jgm.3580","article-title":"Multi-omics analysis reveals that ferroptosis-related gene CISD2 is a prognostic biomarker of head and neck squamous cell carcinoma","volume":"26","author":"Li","year":"2024","journal-title":"J Gene Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2025.02.12","article-title":"Different strategies for cancer treatment: Targeting cancer cells or their neighbors","volume":"37","author":"Liu","year":"2025","journal-title":"Chin J Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.7150\/jca.94360","article-title":"Decoding gastric cancer: machine learning insights into the significance of COMMDs family in immunotherapy and diagnosis","volume":"15","author":"Wan","year":"2024","journal-title":"J Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","article-title":"Cancer treatments: Past, present, and future","author":"Sonkin","year":"2024","journal-title":"Cancer Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1669275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:31:18Z","timestamp":1758259878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1669275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2025.1669275"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1669275","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"article-number":"1669275"}}